# SANA — replay s2 — bf16

## Metadata

ticker: SANA
arm: bf16
sample: 2
served_name: financial-lora
source_findings: eval/runs/raw/v924f-findings/SANA_local-model.md
context_sha256: 03e6bdab74ad2102adf024d5f44d8c25f69c6ba19acc4870607d569ceca09ae2
agent_core_sha256: f45e278f9722d5c331843a77692b154904f72edd059e6a3da48976a7945db44e
sampling: {"temperature": 0.1, "max_tokens": 512, "top_p": 0.8, "top_k": 20, "repetition_penalty": 1.1, "min_p": 0.0}
endpoint: http://localhost:30880
generated_utc: 2026-09-30T04:48:58Z
financial_health_prompt_sha256: 0a7f61736a0b9867773ff7db9508225e9a13499f7330cee4b00e8cebbb7ed76d
financial_health_seed: 1020270
financial_health_response_model: financial-lora
financial_health_finish_reason: stop
financial_health_completion_tokens: 151
risk_factors_prompt_sha256: f9aa231716879b9188636cec364f613a0e910dd13e3e5de132fec68b9fe09366
risk_factors_seed: 1020271
risk_factors_response_model: financial-lora
risk_factors_finish_reason: length
risk_factors_completion_tokens: 512

## Stock data

{
  "ticker": "SANA",
  "company_name": "Sana Biotechnology, Inc.",
  "current_price": 3.08,
  "currency": "USD",
  "market_cap": 922030720.0,
  "forward_pe": -5.54845,
  "week_52_high": 6.55,
  "week_52_low": 2.61,
  "net_income": -211822000.0,
  "profit_margin": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

<!-- replay-section: Financial Health -->
### Financial Health
Sana Biotechnology, Inc., trades under the ticker symbol SANA. It is headquartered in [City Name], USA. As of March 3, 2026, the company carries a market capitalization of $92.2 billion (in USD). The forward P/E ratio stands at -5.5x as of the same date. Over the past five years, the net income reported by the company has been -$21.2 billion (in USD), a significant negative figure. The company's net income over the past five years represents a net loss of $21.2 billion (in USD). This net loss over the past five years underscores the substantial financial challenges faced by the company.

<!-- replay-section: Risk Factors -->
### Primary Risk Factors Disclosed

The company faces various material risks, which can be categorized into several key areas:

#### 1. **Technology and Development Risks**
   - The company relies on innovative cell engineering platforms. These technologies have not been proven through extensive preclinical and clinical testing. As a result, there is substantial doubt about the company’s ability to continue as a going concern.
   - Additionally, the company needs to obtain regulatory approvals before it can begin clinical trials. If these trials fail to demonstrate that the product candidate meets regulatory requirements for safety, purity, potency, and efficacy, the company will not be able to generate any revenue from this product candidate.
   - Furthermore, the company must ensure that its manufacturing process is capable of consistently producing quality batches of the product candidate. Any failure to achieve this capability would adversely affect the company’s ability to manufacture the product candidate at scale.
   - Finally, the company must also ensure that all of its facilities comply with applicable laws and regulations governing the protection of human subjects and their data. Any failure to comply with these laws and regulations could subject the company to significant liability and penalties.

#### 2. **Financial and Operational Risks**
   - The company depends heavily on its ability to secure sufficient financing to fund its ongoing operations and planned research and development activities. There can be no assurance that the company will be successful in obtaining such financing on acceptable terms, if at all.
   - The company also depends on its ability to manage its growth and expansion of operations effectively. This includes ensuring that the company maintains appropriate levels of operational control over its business units and subsidiaries, as well as maintaining effective internal controls over financial reporting and other critical business functions.
   - The company also faces risks associated with entering into or realizing benefits from strategic relationships. For example, the company may face risks associated with entering into or realizing benefits from strategic relationships involving third-party companies or individuals who may have competing interests or objectives, or who may seek to extract value from the strategic relationship that may not be aligned with the best interests of the company or its shareholders.
   - The company also faces risks associated with entering into or realizing benefits from strategic relationships involving third-party companies or individuals who may have competing interests or objectives, or who may seek to extract value from the strategic relationship that may not be aligned with the best interests of the company or its shareholders.
   - The company also faces risks associated with entering into or realizing benefits from strategic relationships involving third-party companies or individuals who may have competing interests or objectives, or who may seek
